(PRTG) – Press Releases
-
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
-
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
-
Biohaven Announces Proposed Public Offering of Common Shares
-
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
-
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives
-
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
-
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
-
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
-
Biohaven Highlights Progress Across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference; Established Extensive Portfolio Across 20 Therap
-
Portage Biotech Reports Business and Strategic Update
-
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
-
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update
-
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
-
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
-
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®
-
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
-
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares
-
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES
-
Portage Biotech Announces $6.0 Million Registered Direct Offering
-
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
-
Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
-
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
-
Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Stu
-
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update
-
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
-
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
-
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
-
Biohaven Provides Preliminary EEG Data Update for Kv7 Platform, Regulatory Update on Troriluzole and Other Corporate Updates
-
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
-
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 American S
-
Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference
-
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
-
Biohaven to Present R&D Day at Yale School of Management
-
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
-
Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy
-
Biohaven Reports Fourth Quarter and Full Year 2022 Financial Results and Reports Recent Business Developments
-
Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders
-
Biohaven Announces Presentation at the American Society for Experimental Neurotherapeutics (ASENT) Annual Meeting
-
Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference
-
Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022
-
Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer
-
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
-
Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
-
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
-
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022
-
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor
-
Portage Biotech Presents Updated Data on the Phase 1/2 Trial Evaluating PORT-2 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
Back to PRTG Stock Lookup
